Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,524 people get BAX articles and Market Currents by email alert.
Get email alerts on BAX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
Baxter International Inc. - Special CallTue, May 7
-
Business Wire (May 7, 2013)
-
Business Wire (May 6, 2013)
-
-
Business Wire (Apr 25, 2013)
-
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 24, 2013)
-
-
Business Wire (Apr 18, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
Why We Like Baxter's DividendValuentum • Thu, Oct 25, 2012 -
-
-
-
Baxter Still Defensive, But Is Now The Time For Offense?Stephen Simpson • Tue, May 15, 2012 -
Baxter Earnings PreviewZacks Investment Research • Tue, Apr 17, 2012 -
-
Baxter's A Buy For Growth, Cash Flow, And Rising DividendsIngrid Hendershot • Tue, Mar 13, 2012 -
-
-
-
-
Baxter International Inc. - Special CallTue, May 7
-
Baxter International Q2 2010 Earnings Call TranscriptThu, Jul 22, 2010
-
Baxter International Inc. Q1 2010 Earnings Call TranscriptThu, Apr 22, 2010
-
Baxter International Inc. Q4 2009 Earnings Call TranscriptThu, Jan 28, 2010
-
Baxter International Inc. Q3 2009 Earnings Call TranscriptThu, Oct 15, 2009
-
Baxter International Inc. Q2 2009 Earnings Call TranscriptThu, Jul 16, 2009
-
at CNBC.com (May 7, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 18, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 8, 2013)
-
Business Wire (Mar 27, 2013)
-
Business Wire (Feb 27, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 7, 2013)
-
at CNBC.com (Jan 29, 2013)
-
at CNBC.com (Jan 24, 2013)
BAX vs. ETF Alternatives
Company Description
Baxter develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 7, 1:54 PM Barclays comes to the defense of Baxter (BAX -3.1%) this afternoon, upping the stock to Overweight on today's weakness. The stock was hit after the drug-maker said Phase III testing of its Gammagard treatment for Alzheimer's disease did not meet its co-primary endpoints. Comment! [Healthcare, On the Move]
- Tuesday, May 7, 8:25 AM Baxter International (BAX) slips 2.2% premarket after Phase III testing on its Alzheimer's drug immunoglobulin (IG) - always a long shot - failed to meet its co-primary endpoints. (PR) 1 Comment [Healthcare, On the Move]
- Friday, March 22, 9:29 AM Halozyme Therapeutics (HALO) +18.6% premarket after the European Medicines Agency approves partner Baxter (BAX) for the use of HALO's HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Upon receiving marketing authorization from the EC, BAX plans to launch HyQvia in some European countries later this year. Comment! [Healthcare, On the Move]
- Friday, November 23, 2012, 10:35 AM Baxter International (BAX +1.4%) is in talks on a deal to buy Swedish medical-equipment maker Gambro for roughly $4B. Though still in its early stages, the companies are aiming to complete a deal within the next two to three weeks. Comment! [Healthcare, On the Move, M&A]
- Wednesday, August 1, 2012, 7:24 PM Baxter (BAX) confirms it's received a complete response letter from the FDA delaying the approval of its investigational product HyQ. More specifically, the agency says it's seeking additional preclinical data focusing on issues related to non-neutralizing antibodies and the possible effects they have on reproduction, development and fertility. HyQ, which is in development with Halozyme Therapeutics (HALO), is a treatment that aims to allow physicians to tailor antibody drug therapy to the needs of patients with immune-system disorders. BAX -0.6%, HALO -54% AH. Comment! [Healthcare, On the Move]
- Wednesday, July 25, 2012, 12:49 PM In addition to raising its dividend by 34% this morning, Baxter International (BAX +2.9%) also approves a new $2B stock buyback program, as the health-care company looks to share the wealth and boost shareholder value. BAX has benefited recently on strong demand for its hemophilia and immunodeficiency products, and because of its product focus on life-threatening ailments and injuries, the company has been less impacted by the slowdown in health-care spending than its peers. 1 Comment [Healthcare, On the Move]
- Tuesday, June 19, 2012, 8:06 AM Shares of Baxter International (BAX) gain 1.1% premarket after Goldman Sachs adds the company to its Conviction Buy List on a valuation call and with the potential of its pipeline and another dividend increase looming for H2. Comment! [On the Move, Consumer]
- Monday, April 16, 2012, 9:22 AM Baxter International (BAX) trades 3.8% lower premarket after it discloses along with partner Halozyme Therapeutics that the FDA needs more long-term data on their jointly-developed HyQ product. Comment! [Healthcare, On the Move]
-
Monday, April 16, 2012, 9:05 AM
Premarket gainers: ECYT +114%. DRJ +30%. CSIQ +9%. SQNM +9%. LDK +7%. TSL +6%. RENN +4%. YGE +4%. STX +4%. JASO +4%. STP +4%. ANR +3%.
Losers: PCO -47%. HALO -22%. SANG -5%. BAX -4%. MAT -4%. RBS -3%. VALE -3%. Comment! [On the Move] - Thursday, December 22, 2011, 4:32 PM Momenta Pharmaceuticals (MNTA) gains 5.7% AH after announcing it has entered into a collaboration with Baxter (BAX) to develop a class of drugs called biosimilars. As part of the deal, Baxter will make a $33M up-front payment to Momenta related to the development of six drug compounds, and "may make additional payments over the next several years." 1 Comment [Healthcare, On the Move]
- Tuesday, December 13, 2011, 8:31 AM Diversified medical products giant Baxter (BAX) announces it's acquiring surgical device maker Synovis (SYNO) for $28/share, or $260M after adjusting for net cash. The price represents a 52% premium to Synovis' Monday close. Baxter expects the deal, which is expected to close in Q1, will be dilutive to its 2012 EPS by $0.04, but will be neutral to 2013 EPS, and accretive afterwards. Comment! [Healthcare, On the Move, M&A]
- Tuesday, September 27, 2011, 11:23 AM Baxter (BAX +5.1%) gains after JP Morgan raises it to overweight, citing a solid product pipeline and the potential for revenue and EPS growth through 2013. Comment! [Healthcare, On the Move]
- Tuesday, September 20, 2011, 3:11 PM Teva (TEVA -2.8%) dips after Baxter (BAX +1.9%) wins a bid to force the company to pay all costs relating to claims that tainted vials of propofol caused colonoscopy patients to develop hepatitis. Comment! [Healthcare, On the Move]
- Thursday, August 25, 2011, 10:41 AM Baxter International (BAX -1.95%) buys privately held Baxa Corp. for $380M in cash in an effort to expand its portfolio of nutrition products and drug delivery systems. Comment! [Healthcare, On the Move]
-
WhisperNumber
Alerts issued this morning for $AXP, $BAX, $FITB, $UNP, and $VZ. http://bit.ly/17e4eoA - View all 0 replies
-
WhisperNumber
$BAX earnings $1.05, seven cents short of the whisper number. Expected price reaction: http://seekingalpha.com/a/swgf - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Julius Ferraro
Out of BAX and into HAL. I've never had a better 3 days of trading. Doubled my gains for the year in 3 days :) - View all 0 replies
-
- View all 0 replies
LATEST REPLIES